Elsevier Inc.

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Abu-Rustum
    Abu-Rustum
  3. Chi
    Chi
  4. O'Cearbhaill
    O'Cearbhaill
  5. Hensley
    Hensley
  6. Leitao
    Leitao
  7. Sonoda
    Sonoda
  8. Iasonos
    Iasonos
  9. Alektiar
    Alektiar
  10. Tew
    Tew

Groups

  1. Gynecologic Medicine Service (359)
  2. Gynecology Disease Management Team (359)
  3. Solid Tumor Oncology Division (359)
  4. Department of Medicine (358)
  5. GDMT, Medicine (357)
  6. Surgery (209)
  7. GDMT, Surgery (195)
  8. GDMT, Pathology and Laboratory Medicine (92)
  9. Survivorship Research (90)
  10. Epidemiology and Biostatistics (83)
Search Within
  1. "Gynecologic Medicine Service"
  2. "Gynecologic Oncology"
Formats
  1. Journal Article (232)
  2. Meeting Abstract (116)
  3. Review (7)
  4. Editorial (2)
  5. Correspondence (1)
  6. Guidelines (1)
Groups
  1. Gynecologic Medicine Service (359)
  2. Gynecology Disease Management Team (359)
  3. Solid Tumor Oncology Division (359)
  4. Department of Medicine (358)
  5. GDMT, Medicine (357)
  6. Surgery (209)

More Groups

People
  1. Carol Aghajanian (174)
  2. Nadeem Abu-Rustum (131)
  3. Dennis Chi (112)
  4. Richard Barakat (85)
  5. Roisin O'Cearbhaill (73)
  6. Martee Hensley (72)

More People

Years
  1. 2024 (4)
  2. 2023 (41)
  3. 2022 (30)
  4. 2021 (33)
  5. 2020 (45)
  6. 2019 (11)

More Years

Publications
  1. Gynecologic Oncology (359)

Results (359)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes
    Journal Article

    Praiss, A. M.; White, C.; Iasonos, A.; Selenica, P.; Zivanovic, O.; Chi, D. S.; Abu-Rustum, N. R.; Weigelt, B.; Aghajanian, C.; Girshman, J.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
    Journal Article

    Friedman, C. F.; D'Souza, A.; Bello Roufai, D.; Tinker, A. V.; de Miguel, M.; Gambardella, V.; Goldman, J.; Loi, S.; Melisko, M. E.; Oaknin, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
    Journal Article

    Kahn, R. M.; Selenica, P.; Boerner, T.; Roche, K. L.; Xiao, Y.; Sia, T. Y.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Modern associations of uterine carcinomas with prior exposure to tamoxifen
    Meeting Abstract

    Rios-Doria, E.; Hodgson, A.; Aviki, E.; Zivanovic, O.; Friedman, C.; Aghajanian, C.; Makker, V.; Liu, Y.; Zamarin, D.; Leitao, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcoma
    Meeting Abstract

    Sia, T.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M.; Rubinstein, M.; Makker, V.; Grisham, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Makker, V.; Vergote, I.; Mirza, M.; Coleman, R.; Fidalgo, J. A. P.; Monk, B.; Valabrega, G.; Slomovitz, B.; van Gorp, T.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes
    Meeting Abstract

    Praiss, A.; Park, K.; Zhou, Q.; White, C.; Iasonos, A.; Zivanovic, O.; Abu-Rustum, N.; Weigelt, B.; Aghajanian, C.; Grisham, R.
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Characterization of tumor response with lenvatinib plus pembrolizumab in study 309/KEYNOTE-775
    Meeting Abstract

    Makker, V.; Lorusso, D.; Moore, R.; Miller, D.; Mackay, H.; Santin, A.; Ushijima, K.; Kim, Y. M.; Sanli, U.; Yonemori, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Real-world outcomes and adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer
    Meeting Abstract

    Zammarrelli, W.; Ma, W.; Espino, K.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N.; Aghajanian, C.; Green, A.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save